Biogen to Acquire Apellis for $5.6B to Strengthen Immunology PortfolioZacks Investment Research • 04/01/26
Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives TranscriptSeeking Alpha • 03/31/26
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolioProactive Investors • 03/31/26
Biogen Snaps Up Apellis Pharma For $5.6 Billion, But Biogen Dives As Apellis SoarsInvestors Business Daily • 03/31/26
Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseasesMarket Watch • 03/31/26
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into NephrologyGlobeNewsWire • 03/31/26
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.GlobeNewsWire • 03/31/26
Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular AtrophyBenzinga • 03/30/26
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular AtrophyGlobeNewsWire • 03/30/26
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease ActivityGlobeNewsWire • 03/28/26
Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous BiologicsPRNewsWire • 03/25/26
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026GlobeNewsWire • 03/20/26
Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class ActionGlobeNewsWire • 03/19/26
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual MeetingGlobeNewsWire • 03/19/26